Skip to main content
Top
Published in: Rheumatology International 9/2019

01-09-2019 | Gout | Pharmacovigilance

Pharmacist-managed titration of urate-lowering therapy to streamline gout management

Authors: Irvin J. Huang, Jean W. Liew, Meredith B. Morcos, Silu Zuo, Carol Crawford, Alison M. Bays

Published in: Rheumatology International | Issue 9/2019

Login to get access

Abstract

The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines. Adherence to urate-lowering therapy (ULT) can be difficult for patients due to barriers, which include medication burden, financial hardship, and lack of medical literacy. Our aim was to create a pharmacist-managed referral for the titration of ULT to target serum uric acid (sUA) levels in a complex patient population. We utilized a clinical database to query patients seen at a rheumatology clinic over a 12-month period with an ICD-10 diagnosis for gout. The referral criteria were indications for ULT per the 2012 ACR guidelines. Rheumatology providers, consisting of attendings, fellows, and a physician assistant, were asked to refer the identified patients to the pharmacist-managed titration program. The intervention group consisted of 19 referred patients and the control group consisted of 28 non-referred patients. The baseline sUA (median (IQR)) at the time of referral was 8.8 (2) mg/dL for the intervention group and 7.6 (2.8) mg/dL for the control group (p = 0.2). At the end of the study period, the sUA was 6.1 (1.4) mg/dL for the intervention group and 6.8 (3.2) mg/dL for the control group (p = 0.08). At the end of the study period, 6 of 19 (32%) intervention group and 7 of 28 (25%) control group were at goal (p = 0.3). A newly instituted pharmacist-managed titration program was able to achieve lower average sUA levels in referred patients compared to demographically similar individuals who received standard gout management.
Literature
1.
go back to reference Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63:3136–3141CrossRefPubMed Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63:3136–3141CrossRefPubMed
2.
go back to reference Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125:679–687CrossRefPubMed Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125:679–687CrossRefPubMed
3.
go back to reference Vincent ZL, Gamble G, House M et al (2017) Predictors of mortality in people with recent-onset gout: a prospective observational study. J Rheumatol 44:368–373CrossRefPubMed Vincent ZL, Gamble G, House M et al (2017) Predictors of mortality in people with recent-onset gout: a prospective observational study. J Rheumatol 44:368–373CrossRefPubMed
4.
go back to reference Singh JA, Sarkin A, Shieh M et al (2011) Health care utilization in patients with gout. Semin Arthritis Rheum 40:501–511CrossRefPubMed Singh JA, Sarkin A, Shieh M et al (2011) Health care utilization in patients with gout. Semin Arthritis Rheum 40:501–511CrossRefPubMed
6.
go back to reference De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V (2014) Medication adherence in gout: a systematic review. Arthritis Care Res 66:1551–1559CrossRef De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V (2014) Medication adherence in gout: a systematic review. Arthritis Care Res 66:1551–1559CrossRef
7.
go back to reference Oderda GM, Shiozawa A, Walsh M et al (2014) Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med 126:257–267CrossRefPubMed Oderda GM, Shiozawa A, Walsh M et al (2014) Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med 126:257–267CrossRefPubMed
8.
go back to reference Roddy E, Zhang W, Doherty M (2007) Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 66:1311–1315CrossRefPubMedPubMedCentral Roddy E, Zhang W, Doherty M (2007) Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 66:1311–1315CrossRefPubMedPubMedCentral
9.
go back to reference Robinson PC, Taylor WJ, Dalbeth N (2015) An observational study of gout prevalence and quality of care in a National Australian General Practice Population. J Rheumatol 42:1702–1707CrossRefPubMed Robinson PC, Taylor WJ, Dalbeth N (2015) An observational study of gout prevalence and quality of care in a National Australian General Practice Population. J Rheumatol 42:1702–1707CrossRefPubMed
10.
go back to reference Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446CrossRef Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446CrossRef
11.
go back to reference R Development Core Team (2005) R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. http://www.R-project.org. Accessed 26 Sept 2018 R Development Core Team (2005) R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. http://​www.​R-project.​org. Accessed 26 Sept 2018
12.
go back to reference Doherty M, Jenkins W, Richardson H et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392:1403–1412CrossRefPubMedPubMedCentral Doherty M, Jenkins W, Richardson H et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392:1403–1412CrossRefPubMedPubMedCentral
13.
go back to reference Lim AYN, Shen L, Tan CH et al (2012) Achieving treat to target in gout: a clinical practice improvement project. Scand J Rheumatol 41:450–457CrossRefPubMed Lim AYN, Shen L, Tan CH et al (2012) Achieving treat to target in gout: a clinical practice improvement project. Scand J Rheumatol 41:450–457CrossRefPubMed
14.
go back to reference Goldfien R, Pressman A, Jacobson A, Ng M, Avina A (2016) A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Perm J 20:18–23 Goldfien R, Pressman A, Jacobson A, Ng M, Avina A (2016) A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Perm J 20:18–23
Metadata
Title
Pharmacist-managed titration of urate-lowering therapy to streamline gout management
Authors
Irvin J. Huang
Jean W. Liew
Meredith B. Morcos
Silu Zuo
Carol Crawford
Alison M. Bays
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04333-5

Other articles of this Issue 9/2019

Rheumatology International 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.